Skip to search formSkip to main contentSkip to account menu

nemorubicin

A morpholinyl analogue of the anthracycline doxorubicin with antineoplastic activity. Nemorubicin is metabolized via the P450 CYP3A enzyme to a… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Doxorubicin
Nemorubicin Hydrochlorideanalogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies
  • U. Grawunder
  • Experimental and Molecular Therapeutics
  • 2018
  • Corpus ID: 81241385
Background: Antibody Drug Conjugates (ADCs) target highly potent small molecule cytotoxic agents to tumors via tumor-specific… 
2016
2016
Abstract 4858: LADR™: A novel linker activated drug release technology for drug delivery
Drug delivery systems in oncology for treating cancer are based on different drug release mechanisms at the tumor site including… 
2013
2013
Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Anthracyclines are one of the most widely used… 
2009
2009
Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results.
4593 Background: Nemorubicin is a novel DNA-intercalator, mainly metabolized in liver by CYP3A4 enzyme and showing synergic… 
Review
2007
Review
2007
Ongoing phase I and II studies of novel anthracyclines
Many anthracyclines are currently in clinical development with the common aim of improving selectivity. This could be achieved by… 
2007
2007
Nemorubicin synergizes with agents currently used for the treatment of hepatocellular carcinoma (HCC)
A277 Nemorubicin (39-deamino-39-[2-(S)-methoxy-4-morpholinyl]doxorubicin hydrochloride) is a “non-conventional” anthracycline in… 
2007
2007
Nucleotide excision repair (NER) plays a central role in the mechanism of action of nemorubicin: Silencing of XPG as a mechanism of resistance
A169 Nemorubicin (39-deamino-39-[2(S) methoxy-4-morpholinyl]doxorubicin-hydrochloride), a doxorubicin derivative obtained by… 
2006
2006
Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines
3845 Nemorubicin is a potent antitumor agent currently in Phase II clinical studies for the treatment of primary hepatocellular… 
2003
2003
INVOLVEMENT OF MURINE CYTOCHROME P450 3A ENZYMES IN THE BIOACTIVATION OF METHOXYMORPHOLINYL DOXORUBICIN (NEMORUBICIN)
Background: Methoxymorpholinyl doxorubicin (nemorubicin; MMDX), a doxorubicin (DX) derivative bearing a methoxymorpholinyl group… 
Review
2001
Review
2001
Targeted cytotoxic analogs of luteinizing hormone-releasing hormone: a reply.
We read with great interest the Highlight Review by Dr CG rundker entitled 'Cytotoxic luteinizing hormone- releasing hormone… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)